The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 782,597 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 15.29% since April 7, 2016 and is downtrending. It has underperformed by 21.43% the S&P500.
The move comes after 8 months negative chart setup for the $1.57 billion company. It was reported on Nov, 11 by Barchart.com. We have $2.36 PT which if reached, will make TSE:PLI worth $125.60 million less.
ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage
Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $4.94 average target is 92.97% above today’s ($2.56) stock price. ProMetic Life Sciences Inc. has been the topic of 18 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets on Friday, October 21 with “Outperform”. Scotia Capital maintained the stock with “Outperform” rating in Monday, August 10 report. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, December 15 report. The stock of ProMetic Life Sciences Inc. (TSE:PLI) has “Outperform” rating given on Thursday, October 27 by Scotia Capital. As per Tuesday, December 8, the company rating was maintained by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Thursday, October 27 with “Outperform”. The firm has “Outperform” rating given on Wednesday, June 15 by RBC Capital Markets. The company was maintained on Thursday, August 11 by Scotia Capital. The firm earned “Speculative Buy” rating on Thursday, October 27 by TD Securities. The stock has “Outperform” rating given by RBC Capital Markets on Thursday, August 25.
More news for ProMetic Life Sciences Inc. (TSE:PLI) were recently published by: Marketwatch.com, which released: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016. Prnewswire.com‘s article titled: “Telesta Therapeutics Inc. announces closing of arrangement with Prometic Life …” and published on October 31, 2016 is yet another important article.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.57 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.